A/Prof Matthew Ku
Honorary Clinical Associate Professor
Department of Medicine
152 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Patient-Reported Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab plus Gemcitabine and Oxaliplatin in STARGLO
DOI: 10.1016/j.clml.2026.10.0072026
Journal article
Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
DOI: 10.1200/JCO-26-018002026
Journal article
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
DOI: 10.1200/JCO-26-009472026
Journal article
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
DOI: 10.1182/bloodadvances.20260200122026
Journal article
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO
DOI: 10.1182/bloodadvances.20260197642026
Journal article
ABCL-483: Glofitamab Plus Gemcitabine and Oxaliplatin vs Rituximab Plus GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Outcomes From the 3-Year Follow-Up of STARGLO
DOI: 10.1016/s2152-2650(26)02565-62026
Journal article
POSTER: ABCL-483: Glofitamab Plus Gemcitabine and Oxaliplatin vs Rituximab Plus GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Outcomes From the 3-Year Follow-Up of STARGLO
DOI: 10.1016/s2152-2650(26)01096-7
RECENT SCHOLARLY WORKS
2026
Journal article
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial
DOI: 10.1016/S0140-6736(26)00866-42026
Journal article
Safety and efficacy of Azer-cel, an allogeneic CD19 CAR T for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia not previously exposed to autologous CAR T therapy.
DOI: 10.1200/jco.2026.44.16_suppl.70122026
Journal article
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation
DOI: 10.1182/bloodadvances.2025017914